CoChat

Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective

The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.

Abstract

Several regulatory guidances on the use of physiologically based pharmacokinetic (PBPK) analyses and physiologically based biopharmaceutics model(s) (PBBM(s)) have been issued. Workshops are routinely held, demonstrating substantial interest in applying these modeling approaches to address scientific questions in drug development. PBPK models and PBBMs have remarkably contributed to model-informed drug development (MIDD) such as anticipating clinical PK outcomes affected by extrinsic and intrinsic factors in general and specific populations. In this review, we proposed practical considerations for a "base" PBPK model construction and development, summarized current status, challenges including model validation and gaps in system models, and future perspectives in PBPK evaluation to assess a) drug metabolizing enzyme(s)- or drug transporter(s)- mediated drug-drug interactions b) dosing regimen prediction, sampling timepoint selection and dose validation in pediatric patients from newborns to adolescents, c) drug exposure in patients with renal and/or and hepatic organ impairment, d) maternal-fetal drug disposition during pregnancy, and e) pH-mediated drug-drug interactions in patients treated with proton pump inhibitors/acid-reducing agents (PPIs/ARAs) intended for gastric protection. Since PBPK can simulate outcomes in clinical studies with enrollment challenges or ethical issues, the impact of PBPK models on waivers and how to strengthen study waiver is discussed.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11095-022-03274-2

Cites

173 of 173 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Research works printed but not linked: 8

  1. FDA. M-CERSI Workshop: Assessing Changes in Pharmacokinetics of Drugs in Liver Disease. 2020.
  2. Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications Philadelphia : Wolters Kluwer Health/Lippincott William & Wilkins, 2011.
  3. Lin W, Yan J, Heimbach T, He H. Pediatric Physiologically Based Pharmacokinetic Model Development: Current Status and Challenges. J Pharm Sci. 2018;4:491–501.
  4. Dodd S, Kollipara S, Sanchez-Felix M, Kim H, Meng Q, Beato S, Heimbach T. Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface. J Pharm Sci. 2019;108(1):87–101. · DOI
  5. Edlund H, Bellanti F, Liu H, Vishwanathan K, Tomkinson H, Ware J, Sharma S, Buil-Bruna N. Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach. British Journal of Clinical Pharmacology;n/a(n/a).
  6. Miller BE, Mistry S, Smart K, Connolly P, Carpenter DC, Cooray H, Bloomer JC, Tal-Singer R, Lazaar AL. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects. BMC Pharmacol Toxicol. 2015;16(1):18. · DOI
  7. Bloomer JC, Ambery C, Miller BE, Connolly P, Garden H, Henley N, Hodnett N, Keel S, Kreindler JL, Lloyd RS, Matthews W, Yonchuk J, Lazaar AL. Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations. Eur J Pharm Biopharm. 2017;117:224–31. · DOI
  8. Keyvanjah K, Fang P, Cooke B, DiPrimeo D, Pearl J, Dyla S, Hunt D, Rubets I, Wong A, Martin D. A drug-drug interaction study evaluating the effect of multiple doses of ranitidine administered once daily or staggered twice daily on the pharmacokinetics and safety of neratinib in healthy subjects. JACCP journal of the american college of clinical pharmacy. 2018;1(2):123‐.

Cited by

See all 164

Metadata

Authors
Lin, W., Chen, Y., Unadkat, J. D., Zhang, X., Wu, D., & Heimbach, T.
Affiliations
  • Janssen Research & Development (United States) (US)
  • Genentech (US)
  • University of Washington (US)
  • United States Food and Drug Administration (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Zhang, Xinyuan
Venue
Pharmaceutical Research
Published
2022-05-13
Volume
39
Issue
8
Pages
1701-1731
ISSN
  • 0724-8741 (ISSN-L)
  • 1573-904X
OpenAlex
W4280544609
Cited by
137
References
173
Citations by year
2026: 18 · 2025: 40 · 2024: 43 · 2023: 24 · 2022: 12
FWCI
7.63
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Pharmaceutical Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
physiologically based pharmacokinetic modeling, physiologically based biopharmaceutics modeling, model-informed drug development, regulatory guidelines, model validation, drug-drug interactions, drug-metabolizing enzymes, drug transporters, pediatric dosing, renal dysfunction, liver dysfunction, pregnancy, proton pump inhibitors, acid-reducing agents
MeSH terms
Adolescent, Biopharmaceutics, Child, Computer Simulation, Drug Interactions, Humans, Infant, Newborn, Models, Biological

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.